Given bilateral hip X‑ray showing mild degenerative changes with chondrocalcinosis consistent with calcium pyrophosphate deposition disease, moderate degenerative changes of the symphysis pubis and lower lumbar spine unchanged since [date], and a DEXA scan indicating osteopenia (T‑score –1.6) with severe bilateral hip pain, what management recommendations are appropriate?

Management of Severe Bilateral Hip Pain with CPPD and Osteopenia

For severe bilateral hip pain in the setting of CPPD with concurrent osteoarthritis and osteopenia, initiate NSAIDs with gastroprotection (or low-dose colchicine 0.5–1.0 mg daily if NSAIDs are contraindicated) for chronic symptom control, combined with non-pharmacological measures including patient education, physical therapy for joint mobility, and weight management. 1

Primary Treatment Strategy

The EULAR guidelines explicitly state that OA with CPPD should follow the same treatment objectives and modalities as OA alone, with the caveat that CPPD may add an inflammatory component requiring additional anti-inflammatory management 1. Your patient has chronic symptoms (not an acute flare based on the "no change since [DATE]" notation), placing them in the chronic CPP inflammatory arthritis category.

Pharmacological Management

First-line options (in order of preference):

• NSAIDs with gastroprotection (proton pump inhibitor mandatory given likely older age and chronic use requirements) 1

  • This addresses both the OA pain and the inflammatory component from CPPD
  • Monitor renal function and cardiovascular risk factors closely

• Low-dose colchicine 0.5–1.0 mg daily as alternative or adjunct 1

  • Particularly useful if NSAIDs are contraindicated
  • RCT evidence shows NNT of 2 for >30% pain reduction in knee OA with CPPD 1
  • Monitor for diarrhea and adjust dose accordingly

Second-line options if inadequate response:

• Low-dose oral corticosteroids for chronic inflammatory control 1
• Methotrexate 5–10 mg weekly for refractory cases (uncontrolled trial showed marked improvement in chronic CPPD) 1
• Hydroxychloroquine (RCT showed NNT of 2 for clinical response in chronic inflammatory arthritis with CPPD) 1

Critical Caveat

Avoid intra-articular hyaluronan injections – these can precipitate acute CPPD attacks 1. This is a common pitfall when treating what appears to be simple OA.

Non-Pharmacological Management (Equally Important)

The guidelines emphasize these are not optional add-ons but core treatment components 1:

• Patient education about CPPD nature and chronicity
• Physical therapy focused on maintaining/improving joint mobility and reducing stiffness
• Weight optimization to reduce mechanical stress on hips
• Assistive devices (cane, walker) to offload affected joints during flares

Osteopenia Management

With T-score of -1.6, this patient has osteopenia (not osteoporosis, which requires T-score ≤-2.5). No pharmacological treatment is indicated for osteopenia alone based on bone density. However:

• Ensure adequate calcium (1200 mg daily) and vitamin D (800-1000 IU daily) supplementation
• Weight-bearing exercise as tolerated (also benefits hip OA)
• Reassess DEXA in 2 years to monitor for progression 2
• Consider pharmacological treatment only if fracture risk assessment (FRAX score) indicates high 10-year fracture probability

Screening for Secondary Causes

Screen for metabolic conditions that promote CPPD, particularly if symptoms are severe or patient is younger than typical CPPD demographic 1:

• Serum calcium and PTH (hyperparathyroidism)
• Serum magnesium (hypomagnesemia)
• Iron studies and ferritin (hemochromatosis)
• Alkaline phosphatase (hypophosphatasia)

If any metabolic abnormality is identified, treating the underlying condition is mandatory 1.

When to Escalate

Consider referral to rheumatology if:

• Inadequate response to NSAIDs/colchicine after 8-12 weeks
• Frequent acute flares requiring systemic corticosteroids
• Need for methotrexate or hydroxychloroquine (requires monitoring)
• Uncertainty about diagnosis or presence of atypical features

Monitoring Strategy

• Clinical response at 4-8 weeks (pain reduction, improved function)
• Renal function and CBC if on NSAIDs or colchicine (baseline and every 3-6 months)
• DEXA scan in 2 years to assess osteopenia progression 2
• Radiographs only if clinical deterioration suggests structural progression

The stable radiographic findings suggest this is not rapidly progressive disease, which is reassuring. The focus should be on symptom control and function preservation rather than aggressive imaging surveillance.